期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 472, 期 1-2, 页码 82-87出版社
ELSEVIER
DOI: 10.1016/j.ijpharm.2014.06.012
关键词
Microcapsules; Polycaprolactone; Microfluidics; Therapeutic proteins; Drug delivery
资金
- Academy of Finland [252215, 256394, 1132726]
- University of Helsinki Research Funds
- European Research Council [310892]
- European Research Council (ERC) [310892] Funding Source: European Research Council (ERC)
In this study, microfluidic technology was employed to develop protein formulations. The microcapsules were produced with a biphasic flow to create water-oil-water (W/O/W) double emulsion droplets with ultrathin shells. Optimized microcapsule formulations containing 1% (w/w) bovine serum albumin (BSA) in the inner phase were prepared with poly(vinyl alcohol), polycaprolactone and polyethylene glycol. All the particles were found to be intact and with a particle size of 23-47 mu m. Furthermore, the particles were monodisperse, non-porous and stable up to 4 weeks. The encapsulation efficiency of BSA in the microcapsules was 84%. The microcapsules released 30% of their content within 168 h. This study demonstrates that microfluidics is a powerful technique for engineering formulations for therapeutic proteins. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据